The Cordoba-based startup obtained health authorization, already prints customized treatments, and presents concrete numbers: savings for patients, investment per production unit, and expansion plans in Argentina and abroad.

‍

Thanks to the authorization from the Córdoba Ministry of Health, they have already begun the production and commercialization of their personalized pills. Medical treatments that previously required multiple tablets can now be delivered in a single capsule, custom-designed by doctors for each patient.

The system also allows a treatment regimen to be divided into capsules for day and night, and enables adjustments in safe microdoses without the need to split tablets.

The validation process focused on safety, quality, and dosing precision. Pill.Ar has demonstrated that its system achieves up to five times greater accuracy for small-scale production—commonly known as “compounding”—setting an entirely new standard for the preparation of personalized medications in pharmacies.

‍

‍

Fewer doses, greater adherence, and savings

‍
In practice, the impact is reflected in a reduction of daily pill intake. Some patients have gone from taking 8 or 9 capsules a day to just 1 or 2, grouped by the time of day (day or night).

Additionally, the benefit is also financial. According to the company’s data, Pill.Ar treatments can be 10% to 15% cheaper for personalized supplementation, around 20% for certain nutritional regimens, and up to 30% more affordable for treatments related to sleep disorders, compared to buying all medications separately.

Currently, the platform works with more than 30 active ingredients, including melatonin, magnesium, vitamins, coenzyme Q10, dutasteride, and other drugs used for migraines, anxiety, menopause, hair health, supplementation, and sleep disorders. All are produced from certified raw materials, sourced from authorized pharmaceutical distributors.

‍

‍

The business: B2B and B2C

Pill.Ar’s direct client is the pharmacy. To operate the technology, the point of sale accesses the Pill.Lab printer—entirely developed by the startup—under a licensing model. The approximate investment to incorporate the system is USD 40,000, which includes the equipment, license, training, and operational support.

The technology automates about 75% of the production process and allows the manufacture of multi-layer capsules, separating chemically incompatible active ingredients. Each preparation is made from a digital order generated by the platform, which guides the process step by step, validates doses and interactions, and ensures compliance with method protocols.

Currently, Pill.Ar operates with one authorized pharmacy: Nueva Farmacia Badra, located in the Alto Alberdi neighborhood. In parallel, the company is in advanced discussions with independent pharmacies and chains in other provinces to expand its production network.

On the clinical side, the medications are already being used at the Conci Carpinella Institute, where doctors have been trained in the technology and can prescribe personalized treatments for their patients.

Additionally, the platform receives inquiries from individual patients, who are referred to professionals already working with the method, always under prior medical evaluation.

‍

‍

Fewer doses, greater adherence, and savings

With health authorization underway, the focus is now on expansion. For 2026, Pill.Ar plans to enter CABA, Buenos Aires, Mendoza, Santa Fe, Neuquén, and Tucumán, while also advancing its internationalization. The company already has letters of intent in Chile, including medical centers, and in Spain, where a pharmacy has expressed interest in implementing the method. In parallel, it opened an investment round with tickets starting from USD 20,000, under the modality of irrevocable contributions in exchange for future shares.

Regarding product development, the next strategic focus is on mental health, with treatments aimed at the gradual and controlled withdrawal of antidepressants and benzodiazepines, a segment where dose personalization is key.

With medications already in production, pharmacies operating, and expansion plans defined, Pill.Ar has moved beyond the conceptual stage and started playing on the field of execution.

‍